Modelling the prevalence of HCV amongst people who inject drugs: An investigation into the risks associated with injecting paraphernalia sharing

Drug and Alcohol Dependence

Volumn 133, Issue 1, 2013, Pages 172-179

  Corson, Stephen ^a   Greenhalgh, David ^a   Taylor, Avril ^c   Palmateer, Norah ^b   Goldberg, David ^b   Hutchinson, Sharon ^b,d  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

HCV; Hepatitis C; Injecting paraphernalia; Mathematical modelling; Needle and syringe sharing; PWID

Indexed keywords

WATER;

ARTICLE; CONTROLLED STUDY; DRUG ABUSE; ENDEMIC DISEASE; FILTER; HEPATITIS C; HEPATITIS C VIRUS; INFECTION RISK; INJECTION; MATHEMATICAL MODEL; NAMED GROUPS OF PERSONS; NEEDLE; PEOPLE WHO INJECT DRUG; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SOCIAL BEHAVIOR; SYRINGE; UNITED KINGDOM; VIRUS TRANSMISSION;

HEPATITIS C VIRUS;

HCV; HEPATITIS C; INJECTING PARAPHERNALIA; MATHEMATICAL MODELLING; NEEDLE AND SYRINGE SHARING; PWID;

COMPUTER SIMULATION; HEPATITIS C; HUMANS; MODELS, STATISTICAL; NEEDLE SHARING; PREVALENCE; RISK-TAKING; SCOTLAND; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84884418956     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.05.014     Document Type: Article

References (47)

1. Abdala N., Crowe M., Tolstov Y., Heimer R. Survival of Human Immunodeficency Virus type 1 after rinsing injection syringes with different cleaning solutions. Subst. Use Misuse 2004, 39:581-600.
2. Abdala N., Gleghorn A.A., Carney J.M., Heimer R. Can HIV-1 contaminated syringes be disinfected? Implications for transmission among injection drug users. J. Acquir. Immune Defic. Syndr. 2001, 28:487-494.
3. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bharadwaj M., Bowden D.S., Drummer H., Hellard M.E. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1749-1752.
4. Bialek S., Terrault N. The changing epidemiology and natural history of hepatitis C virus infection. Clin. Liver Dis. 2006, 10:697-715.
5. Cassin S., Geoghegan T., Cox G. Young injectors: a comparative analysis of risk behaviour. Ir. J. Med. Sci. 1998, 167:234-237.
6. Centre for Disease Control Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus. Technical Report 46 1997, Centre for Disease Control, Altanta, GA, USA.
7. Centre for Disease Control Updated US public health service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for post exposure prophylaxis. Technical Report 50 2001, Centre for Disease Control, Altanta, GA, USA.
8. Corson S., Greenhalgh D., Hutchinson S. Mathematically modelling the spread of hepatitis C in injecting drug users. Math. Med. Biol. 2012, 29:205-230.
9. Corson S., Greenhalgh D., Hutchinson S.J. A time since onset of injection model for hepatitis C spread amongst injecting drug users. J. Math. Biol. 2012, 66:935-978.
10. Corson S., Greenhalgh D., Palmateer N., Weir A., Hutchinson S. Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int. J. Drug Policy 2011, 22:102-108.
11. Crofts N., Caruana C., Bowden S., Kerger M. Minimising harm from hepatitis C virus needs better strategies. Br. Med. J. 2000, 321:899.
12. De P., Roy E., Boivin J.F., Cox J., Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J. Viral Hepat. 2008, 15:279-292.
13. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N., Purcell R.H. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140.
14. Gaskin S., Brazil C., Pickering D. The sharing of injecting paraphernalia by intravenous drug users (IDUs) within a Worcestershire cohort, with specific reference to water and filters. Int. J. Drug Policy 2000, 11:423-435.
15. Hahn J.A., Page-Shafer K., Lum P.J., Bourgois P., Stein E., Evans J.L., Busch M.P., Tobler L.H., Phelps B., Moss A.R. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J. Infect. Dis. 2002, 186:1558-1564. http://jid.oxfordjournals.org/content/186/11/1558.full.pdf+html.
16. Health Protection Agency Shooting up. Infections among injecting drug users in the United Kingdom 2012. Technical Report 2012, Health Protection Agency Centre for Infections, Colindale, London, UK.
17. Health Protection Scotland Health Protection Scotland survey of Glasgow IDUs in 2004 2004, Health Protection Scotland, Glasgow, UK.
18. Hutchinson S., Bird S., Taylor A., Goldberg D. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. Int. J. Drug Policy 2006, 17:211-221.
19. Hutchinson S., Taylor A., Goldberg D., Gruer L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990 to 1994: implications for control and prevention of blood-borne viruses. Addiction 2000, 95:931-940.
20. Kamal S.M. Acute hepatitis C. A systematic review. Am. J. Gastroenterol. 2008, 103:1283-1297.
21. Koester S. The process of drug injection. Applying ethnography to the study of HIV risk among IDUs. AIDS, Drugs and Prevention 1996, 133-149. Routledge, London, UK. R. Hartnol, T. Rhodes (Eds.).
22. Mathei C., van Dooreen S., Lemey P., van Damme P., Buntinx F., Vandamme A.M. The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. J. Viral Hepat. 2008, 15:399-408.
23. Mathei C., Shkedy Z., Denis B., Kabali C., Aerts M., Molenderghs G., van Damme P., Buntinx F. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. J. Viral Hepat. 2006, 13:567-570.
24. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., Wodak A., Panda S., Tyndall M., Toufik A., Mattick R.P. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372:1733-1745.
25. MATLAB, 2011. version 7.13.0.564 (R2011b) 2011, The MathWorks Inc., Natick, Massachusetts.
26. Mehta S.H., Astemborski J., Kirk G.D., Strathdee S.A., Nelson K.E., Valhow D., Thomas D.L. Changes in blood-borne infection risk among injection drug users. J. Infect. Dis. 2011, 203:587-594.
27. Mehta S.H., Cox A., Hoovere D.R., Wang X., Mao Q., Ray S., Strathdee S.A., Vlahov D., Thomas D. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
28. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J. Viral Hepat. 2006, 13:34-41.
29. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I. High incidence of hepatitis C virus infection within a cohort of injecting drug users. J. Viral Hepat. 2007, 14:413-418.
30. National Treatment Agency Does syringe cleaning work?? 2009, http://www.harmreductionworks.org.uk/2_films/{set minus}newlinedoes_cleaning _syringes_work.html, Accessed (2010).
31. Needle Exchange Surveillance Initiative The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2007. Technical Report 2008, Health Protection Scotland and the University of the West of Scotland.
32. Needle Exchange Surveillance Initiative The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2008/2009. Technical Report 2010, University of the West of Scotland and Health Protection Scotland and West of Scotland Specialist Virology Centre, Paisley, UK.
33. Nelson P.K., Mathers B.M., Cowie B., Hagan H., des Jarlais D., Horyniak D., Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011, 378:571-583.
34. Palmateer N., Hutchinson S.J., McAllister G., Munro A., Cameron S., Goldberg D., Taylor A. Risk of transmission associated with sharing drug injecting paraphernalia: An analysis of recent hepatitis C infection using cross-sectional survey data 2012, (Unpublished Manuscript).
35. Pouget E.R., Hagan H., des Jarlais D.C. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. Addiction 2012, 107:1057-1065.
36. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J.F., Parent R., Rochefort J., Caessens C., The SurvUDI Working Group High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int. J. STD AIDS 2007, 18:1057-1065.
37. Scottish Government Hepatitis C action plan for Scotland. Phase II: May 2008-March 2011 2008, http://www.scotland.gov.uk/Publications/2008/05/13103055/0.
38. Scottish Government Guidelines for services providing injecting equipment. Best practice recommendations for commissioners and injecting equipment provision (IEP) services in Scotland 2010, http://www.scotland.gov.uk/Publications/2010/03/29165055/0.
39. Simmonds P., Mutimer D., Follett E. Microbiology and Microbial Infections 1998, Arnold, London, UK, (Chapter 35).
40. Speed S. The sharing of injecting paraphernalia among 96 regular attenders at needle exchange schemes in the North West of England: Implications for local public health policy. Int. J. Drug Policy 1998, 9:351-358.
41. Sutton A.J., Gay N.J., Edmunds W.J., Hope V.D., Gill O.N., Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect. Dis. 2006, 6:1-10.
42. The Kirby Institute Austalian NSP survey: Prevalence of HIV. HCV and injecting and sexual behaviour among NSP attendees. National Data Report 1995-2010. Technical Report 2011, The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
43. Thibault V., Bara J.L., Nefau T., Garson C.D. Hepatitis C transmission in injection drug users: could swabs be the main culprit?. J. Infect. Dis. 2011, 12:1839-1842.
44. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R., Garfein R.S. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am. J. Epidemiol. 2002, 155:645-653.
45. Vickerman P., Grebely J., Dore G.J., Sacks-Davis R., Page K., Thomas D.L., Osburn W.O., Cox A.L., Aitken C.K., Hickman M., Hellard M. The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J. Infect. Dis. 2012, 205:1342-1350.
46. Vickerman P., Hickman M., Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing, London case study. Int. J. Epidemiol. 2007, 36:396-405.
47. Vickerman P., Platt L., Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex. Transm. Infect. 2009, 85:23-30.